From: Profile and course of early rheumatoid arthritis in Morocco: a two-year follow-up study
Baseline variable | Value |
---|---|
Sex, % women | 88.2 |
Age, years | 46.9 [24-72] ± 10.8 |
Provenance, % urban/rural | 74.5/25.5 |
Education level | Â |
Analphabet, % | 68.6 |
High level school, % | 3.9 |
Comorbidity, % | 18.6 |
Disease duration, weeks | 24 [6-48] ± 13.9 |
Referral to specialist delay, days | 140 [7-420] ± 100 |
Stiffness duration, mn | 138 [15-360] ± 76 |
Extraarticular manifestations, % | 1.8 |
ESR, mm/hour | 57.2 [5-115] ± 25.8 |
CRP, mg/liter | 26.8 [0-96] ± 22 |
RF positivity, % | 62.5 |
Antibody positivity, % | 7.8 |
ACPA positivity, % | 56.6 |
HLA-DRB1*04, % | 45.1 |
HLA-DRB1*01, % | 11.8 |
Patient global assessment (0-10) | 3.4 [0-8] ± 1.6 |
Physician global assessment (0-10) | 6.2 [1-10] ± 1.7 |
Patient pain assessment (0-10) | 6.6 [1-10] ± 1.8 |
Tender joint count (0-28) | 20.4 [8-48] ± 10.1 |
Swollen joint count (0-28) | 9.6 ± 6.5 |
HAQ (0-3) | 2.2 [0.7-3] ± 0.6 |
Presence at least of one erosion, % | 27.5 |
Total SVDH score | 1 (0-5)* |
Erosion score | 0 (0-1)* |
Joint space narrowing score | 1 (0-3)* |
Treatment received | Â |
Corticosteroids, % | 35.3 |
DMARD, % | 7.8 |